Certain Financial Statement Caption Information

9 Months Ended

Sep. 30, 2021

Certain Financial Statement Caption Information [Abstract]

Certain Financial Statement Caption Information

4. Certain Financial Statement Caption Information

Short-Term Investments

The following table summarizes the Company’s short-term investments (in thousands):

	Maturity	Amortized		Unrealized		Unrealized			Estimated
	(in years)	Cost		Gains		Losses			Fair Value
September 30, 2021
U.S. treasury securities	1 or less	$	7,544	$	-	$	-		$	7,544
U.S. treasury securities	>1 and <5	$	5,999		-		(4	)		5,995
Total		$	13,543	$	-	$	(4	)	$	13,539
December 31, 2020
U.S. treasury securities	1 or less	$	56,218	$	6	$	(4	)	$	56,220
Certificates of deposit	1 or less		1,955		6		-			1,961
Total		$	58,173	$	12	$	(4	)	$	58,181

All of the Company’s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date. All of the Company’s securities have a maturity within two years of the balance sheet date.

There were no impairments considered other-than-temporary during the periods presented, as it is management’s intention and ability to hold the securities until a recovery of the cost basis or recovery of fair value. For the nine months ended September 30, 2021 and 2020, there were net gross realized gains on short-term investments totaling $0 and $13,000, respectively. Unrealized gains and losses are included in accumulated other comprehensive loss.

Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	September 30,		December 31,
	2021		2020
Accrued payroll and other employee benefits	$	2,285	$	1,870
Clinical studies		1,056		493
Other accruals		168		307
Non-clinical research		281		72
Accrued interest		69		71
Total accrued expenses	$	3,859	$	2,813